Status:
UNKNOWN
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Invasive Pulmonary Aspergillosis
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmona...
Detailed Description
Recently, there has been increasing appreciation of chronic obstructive pulmonary disease (COPD) as an important risk factor of invasive pulmoanry aspergillosis (IPA). However, clinical data on the mo...
Eligibility Criteria
Inclusion
- Proven invasive pulmonary aspergillosis
- Probable invasive pulmonary aspergillosis
- Hospitalized in respiratory wards
- Not having received an empirical antifungal therapy for 72h before inclusion
Exclusion
- A history of allergy to echinocandins
- Severe renal failure, severe hepatic insufficiency
- Inadequately treated bacterial infection
- Documented HIV infection
- Status of pregnancy or lactation
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2014
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01499433
Start Date
January 1 2012
End Date
November 1 2014
Last Update
January 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Institute of Respiratory Diseases
Guangzhou, Guangdong, China, 510120